Beyond The Numbers: 8 Analysts Discuss Teva Pharmaceutical Indus Stock

Throughout the last three months, 8 analysts have evaluated Teva Pharmaceutical Indus TEVA, offering a diverse set of opinions from bullish to bearish.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $14.25, a high estimate of $19.00, and a low estimate of $11.00. Marking an increase of 24.67%, the current average surpasses the previous average price target of $11.43.

Diving into Analyst Ratings: An In-Depth Exploration

The analysis of recent analyst actions sheds light on the perception of Teva Pharmaceutical Indus by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.

Key Insights:

• Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Teva Pharmaceutical Indus. This information provides a snapshot of how analysts perceive the current state of the company.
• Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Teva Pharmaceutical Indus compared to the broader market.
• Price Targets: Understanding forecasts, analysts offer estimates for Teva Pharmaceutical Indus's future value. Examining the current and prior targets provides insight into analysts' changing expectations.

Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Teva Pharmaceutical Indus's market standing. Stay informed and make well-considered decisions with our Ratings Table.

Stay up to date on Teva Pharmaceutical Indus analyst ratings.

Get to Know Teva Pharmaceutical Indus Better

Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the U.S. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a U.S.-based generic and specialty drug distributor.

Unraveling the Financial Story of Teva Pharmaceutical Indus

Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.

Positive Revenue Trend: Examining Teva Pharmaceutical Indus's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 15.77% as of 31 December, 2023, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.

Net Margin: Teva Pharmaceutical Indus's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 10.34%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): Teva Pharmaceutical Indus's ROE excels beyond industry benchmarks, reaching 6.39%. This signifies robust financial management and efficient use of shareholder equity capital.

Return on Assets (ROA): Teva Pharmaceutical Indus's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 1.08%, the company showcases efficient use of assets and strong financial health.

Debt Management: With a high debt-to-equity ratio of 2.68, Teva Pharmaceutical Indus faces challenges in effectively managing its debt levels, indicating potential financial strain.

What Are Analyst Ratings?

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.

This article was generated by Benzinga's automated content engine and reviewed by an editor.